Patents for Toll-like receptor ligands as radiation countermeasures for acute radiation syndrome

Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): A review

(2015) Vijay K. Singh et al.   CYTOKINE

Animal models for acute radiation syndrome drug discovery

(2015) Vijay K Singh et al.   Expert Opinion on Drug Discovery

Biologics as countermeasures for acute radiation syndrome: where are we now?

(2014) Vijay K Singh et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Radiation countermeasure agents: an update (2011 – 2014)

(2014) Vijay K Singh et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Prevention and Mitigation of Acute Radiation Syndrome in Mice by Synthetic Lipopeptide Agonists of Toll-Like Receptor 2 (TLR2)

(2012) Alexander N. Shakhov et al.   PLoS One

CBLB613: A TLR 2/6 Agonist, Natural Lipopeptide ofMycoplasma arginini, as a Novel Radiation Countermeasure

(2012) Vijay K. Singh et al.   RADIATION RESEARCH

EUROPEAN CONSENSUS ON THE MEDICAL MANAGEMENT OF ACUTE RADIATION SYNDROME AND ANALYSIS OF THE RADIATION ACCIDENTS IN BELGIUM AND SENEGAL

(2010) Patrick Gourmelon et al.   HEALTH PHYSICS

Toll-like receptors, wound healing, and carcinogenesis

(2008) Johannes Kluwe et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models

(2008) L. G. Burdelya et al.   SCIENCE